Nanoscale mechanisms in age-related hip-fractures

Shaocheng Ma1,2, En Lin Goh2, Tabitha Tay2, Crispin C. Wiles2,3, Oliver Boughton2, John H. Churchwell2, Yong Wu5, Angelo Karunaratne6, Rajarshi Bhattacharya7, Nick Terrill8, Justin P. Cobb2, Ulrich Hansen1,9 & Richard L. Abel2,9*

Nanoscale mineralized collagen fibrils may be important determinants of whole-bone mechanical properties and contribute to the risk of age-related fractures. In a cross-sectional study nano- and tissue-level mechanics were compared across trabecular sections from the proximal femora of three groups (n = 10 each): ageing non-fractured donors (Controls); untreated fracture patients (Fx-Untreated); bisphosphonate-treated fracture patients (Fx-BisTreated). Collagen fibril, mineral and tissue mechanics were measured using synchrotron X-Ray diffraction of bone sections under load. Mechanical data were compared across groups, and tissue-level data were regressed against nano. Compared to controls fracture patients exhibited significantly lower critical tissue strain, max strain and normalized strength, with lower peak fibril and mineral strain. Bisphosphonate-treated exhibited the lowest properties. In all three groups, peak mineral strain coincided with maximum tissue strength (i.e. ultimate stress), whilst peak fibril strain occurred afterwards (i.e. higher tissue strain). Tissue strain and strength were positively and strongly correlated with peak fibril and mineral strains. Age-related fractures were associated with lower peak fibril and mineral strain irrespective of treatment. Indicating earlier mineral disengagement and the subsequent onset of fibril sliding is one of the key mechanisms leading to fracture. Treatments for fragility should target collagen-mineral interactions to restore nano-scale strain to that of healthy bone.

Bone fragility has long been attributed to a loss of mass, structure, mineral density and reduced tissue material properties1,2. However, few studies have ever investigated nano-level building blocks in fragile or fractured bone3–7, perhaps because of the technical difficulty of imaging bone nanomechanics8. At the nanoscale, the bone matrix is a composite of collagen fibrils and mineral platelets. An understanding of the role of collagen and mineral mechanics in fragility will be essential for developing effective diagnostics and interventions for preventing fractures.

Bone matrix is a mesh of crosslinked collagen fibrils, coated and embedded with mineral platelets. Deformation mechanisms at the nanoscale may explain deformation and damage mechanisms at higher scales of bone’s hierarchical structure, including macroscale (i.e. whole-bone) deformation10 and fracture. Two key nanoscale bone deformation mechanisms in collagen and mineral have been suggested10,11 and both could contribute to bone strength or fragility.

The first involves the collagen fibrils (~ 100’s nm long and 100 nm diameter12) sliding relative to each other when the interfaces between the individual fibrils are sheared beyond breaking point. The basis for this suggested mechanism is an experimental observation that when bone tissue is stretched the strain in nanoscale bone fibrils initially increases linearly with macroscale bone stretch but subsequently reaches a maximum or a plateau, and further stretching of the bone does not lead to a corresponding increase in fibril strain. Such a behaviour of the fibril strain under load may be explained as the fibrils sliding relative to each other15.
The second mechanism involves the mineral platelets (~ 50 nm long, 25 nm wide and 3 nm thick) which behave similarly. Platelets start to slide relative to each other when the interfaces between the collagen and mineral are sheared beyond breaking point; in this paper, this process is called mineral disengagement. The basis for this suggested mechanism is an experimental observation that when bone tissue is stretched the strain in the nanoscale mineral initially increases but subsequently reaches a maximum and further stretching of the bone does not lead to a corresponding increase in mineral strain.

The onset of fibril sliding and/or mineral disengagement under load could be a sign of the initiation of damage in bone, which eventually leads to fracture. The most comprehensive study investigating nanoscale deformation in human bone was carried out by Zimmerman et al., who reported that osteoporotic cortical tissue was prone to fibril sliding, whereas bone treated with bisphosphonate was less prone. To date no studies have examined the mineral part of the matrix. It will be important to study the deformation of both components simultaneously to establish if the initiation of mineral disengagement occurred before or after the initiation of fibril sliding and which mechanism (if any) occurred simultaneously with maximum strength at the tissue level i.e., whether sliding or disengagement initiated the process of fracture.

Such comparisons between collagen and mineral deformation could be important for understanding the role of nanoscale bone mechanics in age-related fractures. In order to fully understand the role of nanoscale mechanics in age-related fractures, the next important research step will be to compare bone nano-mechanics between bone from donors with and without age-related fractures. Such a comparison would allow an assessment of the association between impaired nanoscale mechanics and age-related fractures.

Aims
The main purpose of this study was to investigate the role of fibril sliding and mineral disengagement (represented by peak fibril and mineral strain respectively) in age-related fractures. In a cross-sectional study nano- and tissue-level mechanical properties were compared across trabecular bone samples from the proximal femora of three groups: ageing donors that had not suffered a fracture (Controls) and ageing fracture patients, both untreated (Fx-Untreated) and bisphosphonate-treated (Fx-BisTreated).

There were three objectives: (1) relate differences in the tissue-level mechanics of the three donor groups to differences in fibril sliding and mineral disengagement (represented by peak fibril and mineral strain respectively); (2) determine which mechanism, fibril sliding or mineral disengagement, initiated the process of fracture by comparing the onset of peak fibrillar, mineral and critical tissue strains (at peak tissue strength) across the three donor groups; and (3) test whether fibril sliding and mineral disengagement were correlated with tissue-level mechanics.

Results
Supplementary Table 1 supplies the raw data for each bone sample including demographic, micro-CT, and mechanical information.

Demographic and bone volume data. The median age of individuals in the Control, Fx-Untreated and Fx-BisTreated groups respectively was 73.0 (IQR 72.3–79.8), 80.0 (76.5–82.0) and 79.5 (76.0–82.0) (Table 1). There were no significant differences in age between the groups (Kruskal Wallis p = 0.135). The median bone volume fraction of the Control, Fx-Untreated and Fx-BisTreated groups respectively was 0.34 (IQR 0.33–0.36), 0.25 (0.24–0.26) and 0.26 (0.25–0.30) (Table 1). Controls possessed a significantly higher BV/TV than the Fx-Untreated and Fx-BisTreated groups and the fracture groups were not significantly different from each other (Kruskal Wallis p = 0.002 and pairwise Mann–Whitney U test Control vs. Fx-Untreated p = 0.001, Control vs. Fx-BisTreated p = 0.034, Fx-Untreated vs. Fx-BisTreated p = 0.251).

Tissue versus nanomechanics. The Control group exhibited the highest critical tissue strain (ε\text{UTS}_{\text{Tissue}}) across all groups, followed by the Fx-Untreated and Fx-BisTreated groups, all of which were statistically significant Kruskal Wallis p < 0.001 (Fig. 1a). The Fx-BisTreated group exhibited the lowest critical tissue strain (ε\text{UTS}_{\text{Tissue}}).

The Control group exhibited the highest maximum tissue strain across all groups, followed by the Fx-Untreated and Fx-BisTreated groups, all of which were statistically significant Kruskal Wallis p < 0.001 (Fig. 1b). The Fx-BisTreated group exhibited the lowest maximum tissue strain.

The Control group exhibited the highest strength across all groups, followed by the Fx-Untreated and Fx-BisTreated groups, all of which were statistically significant Kruskal Wallis p < 0.001 (Fig. 1c). The Fx-BisTreated group exhibited the lowest tensile strength. Figure 1c presents the strength normalized for BV/TV as described in the method. The variation of raw strength with BV/TV is provided in Supplementary Fig. 1.

Critical tissue strain versus peak fibril and mineral strains. Stresses and strains were plotted for each of the 30 samples i.e., 10 in each of the 3 groups (Fig. 2). The amalgamation of all 30 data sets is shown in Fig. 3. A least mean square regression on a quadratic model of the data and including 95% confidence intervals was applied to each of the 3 groups and the results of this analysis are shown in Fig. 3. Statistical analyses were calculated using GraphPad Prism 8 (San Diego, California).
The critical tissue strain, peak fibrillar strain and peak mineral strain were all compared across the three donor groups. The critical tissue strain $\varepsilon_{nUTS}^{\text{Tissue}}$, peak fibrillar strain $\varepsilon_{\text{fibril}}^{\text{Tissue}}$ and peak mineral strain $\varepsilon_{\text{mineral}}^{\text{Tissue}}$ are highlighted in Fig. 3 by arrows with dashed lines.

The critical tissue strain (i.e. the point at which the bone sample reached maximum tensile strength and maximum load-carrying capacity) coincided with the peak mineral strain. Note that for all three donor groups the tissue strain at $\varepsilon_{nUTS}^{\text{Tissue}}$ in Fig. 3a and $\varepsilon_{\text{mineral}}^{\text{Tissue}}$ in Fig. 3c were similar.

In contrast, the peak strain in the collagen fibrils occurred after both the critical tissue strain and the peak mineral strain, but before the maximum tissue strain (i.e. the point at which the bone sample fractured). Note that for all three donor groups the tissue strain at $\varepsilon_{\text{fibril}}^{\text{Tissue}}$ in Fig. 3b was higher than the tissue strain at $\varepsilon_{nUTS}^{\text{Tissue}}$ in Fig. 3a and $\varepsilon_{\text{mineral}}^{\text{Tissue}}$ in Fig. 3c. Further, the tissue strain at $\varepsilon_{\text{fibril}}^{\text{Tissue}}$ in Fig. 3b was lower than the max tissue strain in Fig. 3a. Hence peak fibril strain occurred in the region of plastic deformation (i.e. after the bone sample reached the critical strain at nUTS but before reaching the maximum tissue strain).

The tissue strain values at $\varepsilon_{nUTS}^{\text{Tissue}}$, $\varepsilon_{\text{fibril}}^{\text{Tissue}}$ and $\varepsilon_{\text{mineral}}^{\text{Tissue}}$ were compared directly in Table 2. In all 3 groups, the critical tissue strain ($\varepsilon_{nUTS}^{\text{Tissue}}$) and the tissue strain at peak mineral strain ($\varepsilon_{\text{max mineral}}^{\text{Tissue}}$) were identical i.e., within 1%. Whilst the tissue strain at peak fibril strain was higher (5–14%). The differences in strain between $\varepsilon_{nUTS}^{\text{Tissue}}$, $\varepsilon_{\text{max fibril}}^{\text{Tissue}}$ and $\varepsilon_{\text{max mineral}}^{\text{Tissue}}$ were not significant but approached significance for $\varepsilon_{nUTS}^{\text{Tissue}}$ versus $\varepsilon_{\text{max fibril}}^{\text{Tissue}}$ (see Table 2).

Note that the graphs of Fig. 3 were intended to summarise the data for the reader and were created by combining the data points from all 30 samples, whereas Fig. 1 and Table 2 were created by assessing the mechanical response of the 30 samples from individual graphs of each specimen, such as shown in Fig. 2. Hence, the values in the box plot Fig. 1 are slightly different from those in the curves depicted in Fig. 3. However, the principal findings are consistent between Figs. 1 and 3. At the tissue level as well as the nanoscale, the Fx-BisTreated tissue had lower mechanical properties than Fx-Untreated donors which in turn were lower than the Control.
Regression analysis of tissue and nano and level mechanics. The critical tissue strain ($\varepsilon_{\text{UTS}_{\text{Tissue}}}$) was positively correlated with both the peak fibril ($r^2 = 0.80$) and mineral strain ($r^2 = 0.82$) (Fig. 4a). Similarly, the strength values were positively correlated with both the peak fibril ($r^2 = 0.82$) and peak mineral strain ($r^2 = 0.82$) (Fig. 4b).

Discussion
Nan- and tissue-level mechanical properties in the proximal femora were compared between patients that had a fractured neck of femur (with either a bisphosphonate treatment history or without) and fracture-naive individuals (collected from a tissue donor bank). As expected the tissue level properties including critical strain (Fig. 1a), maximum strain to failure (Fig. 1b) and strength (Fig. 1c) were significantly lower in the untreated and bisphosphonate-treated fracture groups (Fx-Untreated and Fx-BisTreated) than in the ageing non-fracture group (Control). The comparison of nanoscale properties was consistent with macroscale properties. Peak strain measured in the fibrils and mineral was significantly lower in the fracture groups than the Control (Fig. 1d,e). Overall the Fx-BisTreated group exhibited the lowest critical tissue strain, maximum strain to failure and strength of the fracture groups (Fig. 1a–c), as well as lowest peak fibril (Fig. 1d) and mineral strain (Fig. 1e), despite the Fx-BisTreated and Fx-Untreated sharing similar BV/TV. Across all three groups, critical tissue strain and strength were strongly and positively correlated with the nanoscale strains (Fig. 4). The critical tissue strain and strength increase with increasing deformability at the nano-level. Overall the data support the conclusion that peak fibril
and mineral strain are important determinants of tissue-level mechanical properties and contribute to reduced critical strain and bone strength in patients with age-related hip-fractures.

Results must be interpreted with caution because these are observational, cross-sectional data with all the potential selection biases that cannot be adjusted for. The pattern of decreasing critical strain and strength at the tissue level and strain at the nano level from Control to Fx-Untreated and Fx-BisTreated groups (Fig. 1a) suggest that fractures are associated with altered material properties at the nanoscale, which contribute to loss of whole-bone strength and therefore increased bone fragility. This interpretation is supported by the positive correlation between tissue-level properties (critical strain and strength) with both peak fibril and peak mineral strain (\( \varepsilon_{\text{max mineral}} \)). Tissue strain is plotted along the x-axis in all three figures allowing a comparison of the occurrence of key events (the peaks) from the nanoscale to the macroscale.

**Bisphosphonates might reduce mineral strain.** Our finding that bone from the Fx-BisTreated group exhibited the lowest critical strain and strength compared to the bone from the Fx-Untreated and Control (Fig. 1a) contributes to the current debate about the effect of bisphosphonate treatment on bone mechanical properties. One possible explanation is that bisphosphonates might reduce mechanical properties by binding to the mineral phase and reducing the mineral’s ability to deform. Evidence for this suggestion comes from experi-
ments where mouse bones soaked in zoledronate for 48 h were found to exhibit reduced work to failure under mechanical testing in comparison to controls. Half of the Fx-BisTreated donors published in this study had been prescribed oral alendronate for between 5 and 13 years (Table 1), which would be considered long-term therapy. Assuming the patients adhered to the prescriptions and took the oral pill correctly. Most clinical guidelines recommend a treatment review should be performed after 5 years of continuous therapy. Therefore, one plausible explanation for the relatively poor performance of the Fx-Bistreated group is that although treatment

Table 2. Association between the critical tissue strain ($\varepsilon_{\text{UTS/Tissue}}$), max fibril ($\varepsilon_{\text{fibril/Tissue}}$) and max mineral ($\varepsilon_{\text{mineral/Tissue}}$) strain respectively. In all 3 groups the critical tissue strain is more closely approximated by the tissue strain at max mineral strain (1%) than the tissue strain at max fibril strain (5–14%). Mean and (StDev) compared using paired ANOVA with Tukey’s post hoc.

| Group        | $\varepsilon_{\text{UTS/Tissue}}$ (%) | $\varepsilon_{\text{max fibril/Tissue}}$ (%) | $\varepsilon_{\text{max mineral/Tissue}}$ (%) | ANOVA $p$ | $\varepsilon_{\text{UTS/Tissue}}$ vs. $\varepsilon_{\text{max fibril/Tissue}}$ $p$ | $\varepsilon_{\text{UTS/Tissue}}$ vs. $\varepsilon_{\text{max mineral/Tissue}}$ $p$ | $\varepsilon_{\text{max fibril/Tissue}}$ vs. $\varepsilon_{\text{max mineral/Tissue}}$ $p$ |
|--------------|-------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| Control      | 1.04 (0.30)                         | 1.18 (0.30)                                   | 1.05 (0.28)                                   | 0.056     | 0.076                                       | 0.985                                       | 0.105                                       |
| Fx-Untreated | 0.72 (0.19)                         | 0.78 (0.22)                                   | 0.73 (0.19)                                   | 0.084     | 0.097                                       | 0.948                                       | 0.168                                       |
| Fx-BisTreated| 0.48 (0.10)                         | 0.55 (0.05)                                   | 0.48 (0.10)                                   | 0.050     | 0.075                                       | 0.994                                       | 0.088                                       |

Figure 3. Overall stress and strain curves for Control, Fx-Untreated and Fx-BisTreated groups. (a) Normalized stress–strain curves indicating the critical ($\varepsilon_{\text{UTS/Tissue}}$) and max tissue strains for each group. Effect sizes (ES) used in the statistical analyses are shown (see Table 2). (b) Fibril-tissue strain curves showing tissue strains to reach peak fibril strain ($\varepsilon_{\text{max fibril/Tissue}}$). (c) Mineral-tissue strain curves showing the tissue strains to reach peak mineral strain ($\varepsilon_{\text{max mineral/Tissue}}$). Shaded areas represent the 95% confidence intervals for $n = 10$ donors per group.
yields improvements in BMD and porosity, following long-term therapy these factors may be offset by nanostructural changes resulting in reduced mineral and fibril capacity to sustain high strain.

It should be noted that there are alternative interpretations of the bisphosphonate data. The reduced nano- and macro-mechanics in the Fx-BisTreated group compared to the Fx-Untreated could reflect other aspects of bone health that affect fragility, for example, mineral density, bone mass or microarchitecture. Fracture groups had similar BV/TV (Table 1) so microarchitecture is unlikely to account for the low strength of Fx-BisTreated patients. Bisphosphonate treatment suppresses bone remodelling and has been associated with an accumulation of micro-cracks which reduce bone strength17. However, cross-sectional, or preferably longitudinal studies of the association between bisphosphonate treatment duration and nanomechanics must fully elucidate the effects of therapy at the nanoscale.

**Mineral component governs bone strength and failure.** Perhaps the most interesting finding of the study is that the maximum strain in the apatite mineral \( \varepsilon_{\text{max mineral}}^{\text{Tissue}} \) coincided with the peak stress at the macroscale \( \varepsilon_{\text{nUTS}}^{\text{Tissue}} \) (Fig. 3a,c, Table 2). This observation implies that when the mineral no longer efficiently contributed to the load-carrying capacity of the matrix (i.e. mineral disengaged), the bone sample also lost load-carrying capacity and failed. Thus, mineral disengagement may play a central role in the macroscopic strength of bone tissue.

**Fibril component resists fracture.** In contrast fibril strain peaked \( \varepsilon_{\text{max fibril}}^{\text{Tissue}} \) in the range of plastic deformation i.e., just after the peak stress at the macroscale \( \varepsilon_{\text{nUTS}}^{\text{Tissue}} \) and well before the bone section fractured (maximum tissue strain) (Fig. 3a,b, Table 2). Thus, fibril sliding, and the damage associated with fibril sliding, seems to represent an early stage in the cascade of events that eventually led to the fracture of the bone on the macroscale.

Energy is required to plastically deform bone beyond the peak strength (i.e. nUTS) until a bone sample fractures (i.e. area under the curve Fig. 3a). This energy is spent making the collagen fibrils slide relative to each other which in turn is the source of the plastic deformation. As a result, the bone tissue is better able to absorb the impact energy during a bump or fall, potentially preventing whole-bone fracture. Hence it seems that while mineral disengagement dominates the load-carrying capacity (i.e. strength) the fibril sliding could be an important mechanism for absorbing energy (during plastic deformation) to stop the bone from fracturing.

**Age-related fractures associated with early mineral disengagement and fibril sliding.** Both mineral disengagement and fibril sliding happened earlier (i.e. at lower tissue strain levels) in the Fx-BisTreated and Fx-Untreated groups relative to the Control group (Fig. 3). Therefore, irrespective of treatment fractured bone was more prone to mineral disengagement, fibril sliding and early damage. Which explains the lower criti-
Role of mineral disengagement and fibril sliding in bone fracture. The association between peak mineral and fibril strains with bone failure and bone fracture respectively were consistent across the three donor groups (Control, Fx-Untreated and Fx-BisTreated). This suggests that the mechanisms which led to reduced strength and fracture involve a reduction in the ability of the mineral phase to contribute to the load-carrying capacity of the bone causing mineral disengagement, then an early onset of fibril sliding, and eventually fracture. Our novel data supports disengagement of apatite mineral from the collagen fibrils is the initiating event of bone failure. At the strains observed in this study, this disengagement could involve separation of the mineral from the fibril and perhaps fracturing of the mineral. Since mineral disengagement and subsequent fibril sliding happen more readily in fractured patients, regardless of treatment status, this could be a clinically important mechanism.

Nano strain influence on whole-bone strength. The central finding of the study is that irrespective of treatment, age-related fractures are associated with reduced deformability of bone-matrix at the nanoscale (Fig. 1). Further, critical strain and strength at the tissue scale are strongly positively correlated with the fibrillar and mineral strain (Fig. 4). Hence it is likely that nano-strains do play a key role in determining whole-bone strength or fragility. Nano-mechanical properties might reduce macroscopic strength, either directly by limiting the ability of a bone to bend and absorb energy during a trip or fall, and/or indirectly by reducing the energy required to form micro-cracks in the collagen-mineral matrix.

Nanoscale fracture initiation. Previous studies have reported a higher micro-crack density in the bone of fracture patients relative to controls. Reduced nano-mechanical performance in bone from fracture patients may be the mechanism. Mineral disengagement and fibril sliding may result in nanoscale fractures, which then propagate to form micro-cracks at the tissue scale, and, eventually, whole-bone fracture. The reduced nanomechanical performance of Fx-Untreated and Fx-BisTreated groups may have led to crack initiation at lower macro stresses or strains than Controls, thereby increasing the risk of a fracture nucleating under traumatic load.

Nanostructure and mechanics. The nanoscale brittleness of fracture patients (Fx-Untreated and Fx-BisTreated) found in this study could be due to an increase in the number of AGE crosslinks between collagen fibrils and/or mineral crystal thickness as has been previously reported with age and bisphosphonate therapy. Such correlations between compositional characteristics and mechanical properties do not prove causation but simple mechanisms could be at work. Crosslinks might reduce the ability of collagen fibrils to slide, thereby reducing the strain for a given load. Similarly, thicker crystals may deform less under load and so exhibit reduced strain and limit bone strength.

Increased cross-linking and mineral crystal size could also reduce fracture toughness and affect the ability of bone to form stable microdamage or predispose the bone to premature microcracks that in subsequent load cycles may initiate whole-bone fracture. Stable damage formation is related to higher toughness and resistance to fracture in bone, while high levels of pre-existing microcracks in Fx-BisTreated treated bone has been related to low strength. Hence, the low strength of Fx-Untreated and Fx-BisTreated treated bone found in this study may be due to a reduced ability to sustain stable damage formation and/or high levels of pre-existing microcracks which in turn might have contributed to the neck of femur fracture. There is a possibility that long-term bisphosphonate could further exacerbate microdamage accumulation by suppressing remodelling and therefore removal of cracks.

Nanomechanics: a new component of age-related bone fragility. Our results on the mechanical properties of bone indicate that (in addition to a loss in bone mass) age-related fractures are associated with poor material i.e., inferior nano-mechanical properties which in turn lead to lower toughness and microcracking (i.e. inability to sustain stable microdamage). Bone remodelling is targeted to microcracks and osteoclastic resorption cavities could cause a stress concentration in the tissue leading to more microcracks, more resorption and eventually perforation of trabeculae. Focal defects lead to loss of connectivity within the overall bone structure and compromise bone strength more significantly than universal thinning. Therefore, impaired nanoscale mechanics could accelerate and focus bone loss leading to a large loss of trabecular strength for minimal loss of mass. To fully understand the mechanisms behind bone fragility fractures and this nano- and micro-mechanical aspects of bone quality need to be investigated in addition to effects on bone mass, structure and metabolism. These studies should include detailed analysis of cross-links, mineral dimensions, collagen-mineral interface, mineral disengagement, fibril sliding, diffuse damage, microcracks, remodeling, perforations, bone mass and fractures.

Limitations of synchrotron scattering and diffraction. Papers publishing bone diffraction experiments often overlook a potentially major limitation of the method which is the small size of the region investigated by the X-ray beam (i.e. beam incident on the sample was 200 μm diameter). Other mechanisms (such as damage occurring outside the beam) could off-load the investigated region suggesting an alternative explanation for the plateauing of fibre and mineral strains seen in Fig. 3. However, if this was the case, the tissue strain to fibril sliding ($\varepsilon_{\text{max fibril}}^{\text{Tissue}}$), and tissue strain to mineral disengagement ($\varepsilon_{\text{Tissue}}^{\text{max mineral}}$), would have been the same for each group of donors. However, for each of the three donor groups, $\varepsilon_{\text{Tissue}}^{\text{max mineral}}$ was higher than $\varepsilon_{\text{Tissue}}^{\text{max fibril}}$, although not significantly so. Thus, an offloading mechanism is unlikely to account for our data.
Further, the reliability of our nanomechanical measurements is supported by a comparison of our data with other work. We found a mean maximum fibril strain in the Fx-Un-treated group of 0.59% (Fig. 1d). In similar studies using SAXD measurements of fibril strain, Gupta and colleagues reported a maximum strain of around 0.40% while Zimmermann and colleagues found a maximum strain of approximately 0.70%. Gupta et al. used bovine bone while Zimmermann et al. used osteoporotic human cortical bone. Bovine bone is stiffer than human bone which may explain the relatively low strains reported by Gupta and colleagues. Using WAXD, Gupta and colleagues also reported maximum mineral strain in the range of 0.15 to 0.20% which is consistent with the mean maximum mineral strain of 0.16% found in this study for the Control group (Fig. 1e). Given that all these studies imaged small regions (a few hundred microns) of a sample and the strain data was similar the measures are likely to be representative of the whole bone.

Our findings were not in complete agreement with the literature concerning the effects of disease and bisphosphonate therapy. Zimmermann and colleagues found a reduction in maximum fibril strain (i.e. a drop in the onset of fibril sliding) of approximately 40% due to osteoporosis. Similarly, we found a 31% reduction in maximum fibril strain of the Fx-Un-treated group compared to the Controls group. However, in complete contrast, we found a drop of 60% in the bisphosphonate-treated group while Zimmermann and colleagues reported that young and bisphosphonate-treated bone had similar onset of fibril sliding and essentially that bisphosphonates had restored the nanomechanical properties of the bone.

The dramatically different findings could be due to the type of tissue because Zimmermann and colleagues tested cortical bone and the mechanical data presented here are from the trabecular bone. Local characteristics of the microarchitecture including porosity, trabecular dimensions, and organisation, could cause the failure process to be more stochastic, especially in the small samples used by both studies. Further, tissue structure might also affect the distribution and penetration of bisphosphonates. Trabecular bone has a higher surface area to volume ratio and is remodelled at higher rates so bisphosphonates might be more concentrated than in cortical tissue. Hence the effect of bisphosphonates on mechanics of trabecular and cortical tissue might also vary.

A final issue that must be considered is the accuracy at which the timing of peak mineral and fibril strains can be measured in the mineral and fibril strain curves (see Fig. 2). The steps in tissue strain are 0.03% (± 0.003 SD), which is the limit for accuracy. The differences between peak mineral and fibril strains were larger i.e., 0.13, 0.05, and 0.07 for the three groups (see Table 2). Hence the strain data did resolve the timing of mineral and fibril peaks.

Nanoscale insights into the material basis of fragility. In the clinical and public consciousness, skeletal fragility is due to osteoporosis i.e., loss of bone mineral density (BMD). Therefore, measurement of BMD is currently the most commonly used densitometric technique for quantifying bone fracture risk and starting bisphosphonate treatment. Usually, the areal bone mineral density (i.e. aBMD) is assessed using a DEXA scan which probably measures the bone mass along the direction of the X-ray projection. Though widely used in clinical practice a lot of evidence suggests that it is not possible to confidently predict who will fracture or track the benefits of bisphosphonate therapy using DEXA.

Although there is some correlation between decreasing aBMD and an increased fracture risk, more than 50% of fragility fractures occur in patients with a normal aBMD. Indeed, low bone mineral density (T-score < −2.5) is not sufficient to predict almost half of the non-vertebral fractures (including hip) in postmenopausal women. Notwithstanding the finding that there is a false positive rate of about 15% which probably leads to unnecessary anxiety and therapeutic prescriptions.

More than a decade ago a more nuanced understanding that skeletal fragility is complex and crosses many hierarchical levels, from macro- to micro- and nano-scale was described. It was thought that nanoscale effects on whole-bone mechanics are independent of the micro- and macro-scale. The data presented here support the theory that age-related fractures are directly dependent on mechanical properties at the nanoscale. We propose that as age-related fractures directly depend on the mechanical properties of the nanoscale, any decrease in mechanical properties at the nanoscale is likely to contribute to hip-fractures: via the mechanisms set out above.

Therefore, bone health assessments based on bone material and nanoscale mechanics might have greater sensitivity and specificity than current tests for diagnosing bone fragility, and higher accuracy for predicting fracture risk which would improve treatment decisions. Hence it is important for future research continues to investigate the nanoscale material basis for bone strength and most importantly the knock-on effects of ageing at the nanoscale on the micro- and macro-scale.

It has long been known that mineral plays a key role in bone strength and it is not just mass or distribution that is important, but rather the mechanical properties of the mineral platelets (and crystals) and the interactions with the collagen fibrils are key. The study of these interactions is a new frontier in bone research.

Conclusion
Age-related fractures were associated with impaired bone nanomechanics i.e., weaker mineral apatite that failed and debonded from the collagen matrix at lower stress leading to earlier fibril sliding and plastic deformation. Mineral strain and fibril strain were directly related to reduced critical strain and strength at the tissue-level which were lower in fractured patients, regardless of treatment status. Overall the data support the conclusion that reduced peak fibril and mineral strain are important determinants of tissue-level mechanical properties and contributed to reduced bone deformability and strength in patients with age-related hip-fractures. Therefore, bone nanomechanics is potentially a clinically important component of age-related fracture fragility.
affect the nanomechanics of bone. Studies investigating how nanomechanics is related to the ability of bone to sustain stable microdamage and to the introduction of pre-existing cracks in the bone are also warranted. Our study adds a new dimension to the fundamental understanding of the pathophysiology of bone fragility and the effects of bisphosphonate treatment. Highlighting the need to move away from the conventional approaches based on bulk bone mineral or mass towards utilizing information about the structural hierarchy and how mechanical properties at each level contribute to strength or fragility. Potentially opening avenues for new diagnostic tests and therapies which will address the nanoscale contribution to fragility. Novel fracture risk treatments could target the advanced glycation endproducts (AGE) collagen crosslinks, the mineral dimensions, and possibly the connections between the mineral and collagen to restore or delay the onset of mineral disengagement and subsequent fibril sliding to match that of healthy bone.

Materials and method
Sample information. Ethical approval was granted by the Imperial College Tissue Bank (R13004) and all patients consented for permission to use excess tissue from hip arthroplasty in research. All procedures performed in this study were in accordance with the ethical standards of the institutional and national research committees and with the 1964 Helsinki Declaration and its later amendments. Patients’ histories of metabolic bone disease and treatment were collected from patient records. All individuals with a history of primary bone disease or underlying disorders such as cancer, which could lead to secondary bone disease were excluded from this study.

A consecutive series of femoral heads were collected from 21 patients with an intracapsular fracture after written informed consent was provided at St Mary’s Hospital (London, United Kingdom) between May 2015 and September 2017. In total, 20 patients were included in the study and one was excluded due to avascular necrosis. Femora from non-fracture donors came from cadavers donated to the Biological Resource Centre (AZ, USA). Medical records and physical assessments were examined to select 10 donors with no history of fractures, bone metabolic disease or treatments. It is important to note that it was not possible to obtain dual-energy X-ray absorptiometry (DXA), fracture risk assessment tool (FRAX) or body mass index (BMI) data for any of the donors.

In total, 30 donors were divided into three groups: an ageing non-fracture control group (Control), an untreated fracture group (Fx-Untreated), and a bisphosphonate-treated fracture group (Fx-BisTreated). Demographic data including age, sex and treatment duration are presented in Table 1.

Sample preparation. Thirty rectangular-shaped standard tensile testing samples were prepared, one from each donor. These samples were sectioned from the region directly superior to the trabecular chiasma in the primary tensile trabecular arcade of the femoral heads (Fig. 5). An initial cut was made at the widest point of the femoral head and a second cut 12 mm proximally. Subsequently, an arc-shaped piece was sectioned by making two more cuts; one along the edge of the fovea capitis (used as a reference point) and one at 90°. A slice was taken from the edge facing the fovea and finally the tensile section cut from the end closest to the chiasma. Each tensile section was 12.0 mm in length, 2.8 mm in width and 1.0 mm in thickness. The small thickness of the samples was necessary to enable accurate x-ray diffraction measurements. The ends of each specimen were potted into a 3D printed holder using dental cement, which served as clamps during the testing and resulted in a gauge length of 6 mm. The specimens were stored at -80°C and only removed from storage for tensile testing.

Micro-CT scanning. Before mechanical testing all 30 of the tensile trabecular sections were imaged using a micro-CT system (Nikon X-Tek HMXST-225; tungsten target; X-Ray beam 180 keV and 200 µA, voxel size 30 µm; 3,124 projections; 360° rotation). Total scan time was 30 min. Scans were used to calculate the bone volume fraction (BV/TV) for the entire tissue section (not just the region which would be imaged using scattering and diffraction). Scans contained 256 grey values and were segmented into binary images using the grey value frequency distribution plot to apply a global threshold at the minima between the two peaks that represented
marrow and bone. The advantage of this method is that variations in bone density or scan performance are taken into account and do not affect structural measurements (e.g. BV/TV). The minima at which the threshold was placed ranged between 190 and 233 for the Controls, 200–225 for the Fx-Untreated and 206–222 for Fx-BisTreated. All of the voxels above the threshold were defined as bone and the values below as background. Bone volume fraction was calculated from the binary images using the BoneJ plugin for ImageJ (v1.49) by dividing the total number of voxels that represented bone by the total number of voxels in the whole scan volume.

**Tensile testing with simultaneous measurements of fibril and mineral strain.** A customized micromechanical testing rig, including a load cell, was used for the experiments. The testing rig was fully calibrated to the I22 Beamline facility settings at Diamond Light Source, United Kingdom, as used previously in other studies. Tensile testing to failure was displacement-controlled, with a strain rate of 0.001 s⁻¹. Specimens were defrosted for 30 min before testing then all tests were conducted at room temperature and the specimens were kept hydrated throughout. A high-speed camera was placed beside the testing rig to track the movement of two ink markers on the testing sample (Fig. 6). The tissue strain in each bone sample was calculated from the relative movement between these two markers. The apparent stress was calculated by dividing the measured load by specimen cross-sectional area and then normalized to remove variation attributable to bone volume by dividing by BV/TV to the power of 1.26.

Tissue-level tensile mechanical properties of each bone sample were calculated by plotting the stress data against strain (Fig. 2a). The load–displacement plots were used to determine the critical tissue strain at maximum load-carrying capacity (ε_{UTS}), the maximum tissue strain to fracture and the normalized ultimate tensile strength (nUTS). Critical tissue strain, rather than the normalized ultimate tensile strength, was the key property used to compare the donor groups (and relate the macromechanics to nanomechanics) as strain is relatively insensitive to differences in BV/TV between groups. However, critical tissue strain and normalized ultimate tensile strength (henceforth referred to as strength) were both included to explain the findings of this study to a broad audience.

Nanostrain measurements take advantage of the repeating nanoscale structure of bone. Mineralised collagen fibrils have a periodic distribution of the mineral that results in a spatial periodicity of 67 nm within the fibrils; this distance referred to as ‘D’ (Fig. 7a). When exposed to X-rays the periodically spaced mineral blocks interact with the beam creating a diffraction pattern (Fig. 7b). Specifically, small-angle X-ray diffraction (SAXD) patterns appear in bone (Fig. 7). When the bone, and hence the fibril, stretch ‘D’ increases (Fig. 7a) which results in a change in the diffraction patterns causing the diffraction peaks move (which is imperceptible to the human eye). The measured movement of diffraction peaks is inversely proportional to the change in D, that is ΔD (Fig. 7a) which results in the fibril strain being calculated as ε_{fibril} = ΔD/D_{unloaded} (Fig. 7d). The procedure to determine the position and movement of the diffraction peaks is described elsewhere. Specifically, we tracked the 3rd order meridional diffraction peak as the 1st order peak was obscured by the high-intensity mineral spectrum. Also, we radially integrated the spectrum from ±15° around the load direction (0°) thereby isolating and capturing the strains in fibres that are oriented predominantly along the load direction. These 0° fibres will be exposed to the largest strain during loading, thus, will be the first to fail. We adopted this approach as we were particularly interested in the mechanisms that initiate failure and hence the strains in these 0° fibres were of primary importance.

The mineral strain was also obtained by tracking the movement of X-ray diffraction peaks. In this case, the lattice spacing of the apatite mineral produces diffraction patterns allowing the change of the length of the c-axis of the crystalline hydroxyapatite mineral to be tracked using the 002-diffraction peak. The mineral strain,
ε_{mineral}, was calculated as the change in c-axis length due to loading divided by the length of the c-axis when
the specimen was unloaded.

The scale of the periodicity of the lattice spacing in the mineral platelets is less than a nanometer, or about 2
orders of magnitude lower than the 67 nm periodicity of the mineralized collagen fibrils. Therefore, the spacing
of the diffraction pattern (which is inversely proportional to the scale of the periodicity) spans a wider angle
in the mineral case. Hence, for the analysis of mineral strain wide-angle X-ray diffraction (WAXD) set up was
required in contrast to the small angle (SAXD) set-up that was used for the analysis of the fibril strain (Fig. 6).

Therefore, the sample-detector distance was 0.175 m and 6.852 m for WAXD and SAXD spectra, respectively
(Fig. 6)46. The detectors used were the PILATUS 2 M and RAPID, which allowed for fast measurements during
the mechanical testing. Samples were scanned in real-time during testing at 2.5-s intervals (X-ray exposure time
of 0.5 s). The wavelength was 1 Å with a corresponding X-ray energy of 12.4 keV. Synchrotron X-ray radiation
may cause bone damage leading to inaccuracies in measured mechanical behaviour. Barth and colleagues51
reported that a radiation dose of less than 30 kGy resulted in minimal bone damage. Hence, the exposure time
was set not to exceed 1 s at each scan to minimise radiation dose.

**Statistical analysis.** Demographic (age), structural (BV/TV) and mechanical data (critical tissue strain,
max tissue strain, strength, peak fibril and mineral strain) were compared between donor groups using non-
parametric statistics because Shapiro–Wilk test revealed some of the data were not normally distributed: includ-
ing Control tissue strain; Fx-Untreated critical strain and fibril strain; Fx-BisTreated tissue and mineral strain.
Descriptives were presented as median and interquartile range and compared between donor groups using
Kruskal–Wallis and pairwise Mann–Whitney U tests.

Tissue-level stresses versus strains curves were plotted for every bone specimen in each of the three groups
and showed peak stress (nUTS), Fig. 2a. Similarly, peak strains were apparent when mineral and fibril strain were
plotted against tissue strain (Fig. 2b,c). The critical tissue strains at nUTS (ε_{nUTS}^{max, Tissue}), max fibril strain (ε_{Tissue}^{max fibril}) and max mineral strain (ε_{Tissue}^{max mineral}) were extracted from these curves for each of the 30 the donors. Then the
associations between the critical strain (ε_{nUTS}^{Tissue}) and the nano-level strains of ε_{Tissue}^{max fibril} and ε_{Tissue}^{max mineral} were
investigated using paired ANOVA with Tukey’s post hoc.

The correlation between tissue-level properties (i.e. critical tissue strain and strength) and the nanoscale
properties (i.e. peak fibril and mineral strain) was investigated using a bivariate linear regression with correlation
coefficient r². The residuals exhibited normal distributions in QQ plots. All statistical analyses were performed.
using IBM SPSS Statistics 23 (Armonk, New York) and the graphs were generated with GraphPad Prism 8 (San Diego, California).

Received: 30 April 2020; Accepted: 13 July 2020
Published online: 26 August 2020

References
1. Budman, K., Aspden, R. & Meakin, J. Compression or tension? The stress distribution in the proximal femur. Biomed. Eng. Online 5, 12 (2006).
2. Yoshibash, Z., Padan, R., Joskowicz, L. & Milgrom, C. A CT-based high-order finite element analysis of the human proximal femur compared to in-vitro experiments. J. Biomech. Eng. 129, 297 (2007).
3. Bailey, A. J., Paul, R. G. & Knott, L. Mechanisms of maturation and ageing of collagen. Mech. Ageing Dev. 106, 1–56 (1998).
4. Burr, D. B. Bone material properties and mineral matrix contributions to fracture risk or age in women and men. J. Musculoskelet. Neuronal Interact. 2, 201–204 (2002).
5. Allen, M. R., Gineyts, E., Leeming, D. J., Burr, D. B. & Delmas, P. D. Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporos. Int. 19, 329–337 (2008).
6. Burr, D. B. Changes in bone matrix properties with aging. Bone 120, 85–93 (2019).
7. Agerbo, S., Kwaczała, A. T., Yang, L., Judek, S. & Miller, L. M. Alterations in collagen and mineral nanostructure observed in osteoporosis and pharmaceutical treatments using simultaneous small- and wide-angle X-ray scattering. Calcif. Tissue Int. 95, 446–456 (2014).
8. Ma, S. et al. Synchrontron imaging assessment of bone quality. Clin. Rev. Bone Miner. Metab. 14, 150–160 (2016).
9. Vashishth, D. The role of the collagen matrix in skeletal fragility. Curr. Osteoporos. Rep. 5, 62–66 (2007).
10. Gupta, H. S. et al. Cooperative deformation of mineral and collagen in bone at the nanoscale. Proc. Natl. Acad. Sci. 103, 17741–17746 (2006).
11. Gupta, H. S. et al. Infrabrillar plasticity through mineral/collagen sliding is the dominant mechanism for the extreme toughness of antler bone. J. Mech. Behav. Biomed. Mater. 28, 366–382 (2015).
12. Georgiadis, M., Müller, R. & Schneider, P. Techniques to assess bone ultrastructure organization: Orientation and arrangement of mineralized collagen fibrils. J. R. Soc. Interface 13, 20160088 (2016).
13. Zimmermann, E. A. et al. Intrinsic mechanical behavior of femoral cortical bone in young, osteoporotic and bisphosphonate-treated individuals in low- and high energy fracture conditions. Sci. Rep. 6, 21072 (2016).
14. Allen, M. R. Recent advances in understanding bisphosphonate effects on bone mechanical properties. Curr. Osteoporos. Rep. 16, 198–204 (2018).
15. Compton, J. et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch. Osteoporos. 12, 43 (2017).
16. National Osteoporosis Guidelines Group (NOGG). Clinical Guideline for the Prevention and Treatment of Osteoporosis. (2017).
17. Ma, S. et al. Long-term effects of bisphosphonate therapy: Perforations, microcracks and mechanical properties. Sci. Rep. 7, 1–10 (2017).
18. Jin, A. et al. The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density. Bone Jt. Res. 6, 602–609 (2017).
19. Nyman, J. S. et al. Age-related effect on the concentration of collagen crosslinks in human osteonal and interstitial bone tissue. Bone 39, 1210–1217 (2006).
20. Saito, M., Mori, S., Mashiba, T., Komatsubara, S. & Marumo, K. Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with inacandron in dogs. Osteoporos. Int. 19, 1343–1354 (2008).
21. Tang, S. Y. et al. Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risendronate or alendronate. Osteoporos. Int. 20, 887–894 (2009).
22. Roscher, P. et al. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29, 185–191 (2001).
23. Zimmermann, E. A. et al. Age-related changes in the plasticity and toughness of human cortical bone at multiple length scales. Proc. Natl. Acad. Sci. USA 108, 14416–14421 (2011).
24. Depalick, D., Qin, Z., Shefelbine, S. J. & Buehler, M. J. Influence of cross-link structure, density and mechanical properties in the mesoscale deformation mechanisms of collagen fibrils. J. Mech. Behav. Biomed. Mater. 52, 1–13 (2015).
25. Garnero, P. et al. Extracellular post-translational modifications of collagen are major determinants of biomechanical properties of fetal bovine cortical bone. Bone 38, 300–309 (2006).
26. Vignet-Carrin, S. et al. Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae. Bone 39, 1073–1079 (2006).
27. Camacho, N. P., Rimmel, C. M., Meyer, R. A., Doty, S. & Boskey, A. L. Effect of abnormal mineralization on the mechanical behavior of X-linked hypophosphatemic mice femora. Bone 17, 271–278 (1995).
28. Farlay, D., Panzer, G., Rey, C., Delmas, P. D. & Boivin, G. Mineral maturity and crystallinity index are distinct characteristics of bone mineral. J. Bone Miner. Metab. 28, 433–445 (2010).
29. Lloyd, A. A. et al. Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance. Proc. Natl. Acad. Sci. 114, 8722–8727 (2017).
30. Zioupos, P., Hansen, U. & Currey, J. D. Microradical damage and the fracture process in relation to strain rate in human cortical bone tensile failure. J. Biomech. 41, 2932–2939 (2008).
31. Stepan, J. J. et al. Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 41, 378–385 (2007).
32. Follet, H. et al. Effects of preexisting microdamage, collagen cross-links, degree of mineralization, age, and architecture on compressive mechanical properties of elderly human vertebral trabecular bone. J. Orthop. Res. 29, 481–488 (2011).
33. Burr, D. B., Martin, R. B., Schaffler, M. B. & Radin, E. L. Bone remodeling in response to in vivo fatigue microdamage. J. Biomech. 18, 189–200 (1985).
34. McNamara, L. M. & Prendergast, P. J. Perforation of cancellous bone trabecular by damage-stimulated remodelling at resorption pits: A computational analysis. Artic. Eur. J. Morphol. 42, 99 (2005).
35. Pizazian, M., van der Geest, S. & Miller, P. Bisphosphonates and bone quality. Bonekey Rep. 3, 529 (2014).
36. Kanis, I. A. & Kanis, J. A. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report. Osteoporos. Int. 4, 368–381 (1994).
37. Compston, J. E., McClung, M. R. & Leslie, W. D. Osteoporosis. Lancet 393, 364–376 (1999).
38. Sanders, K. M. et al. Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective? Bone 38, 694–700 (2006).
39. Schuit, S. C. et al. Fracture incidence and association with bone mineral density in elderly men and women: The Rotterdam Study. Bone 34, 195–202 (2004).
40. Marshall, D., Johnell, O. & Wedel, H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312, 1254–1259 (1996).
41. Ruppel, M. E., Miller, L. M. & Burr, D. B. The effect of the microscopic and nanoscale structure on bone fragility. Osteoporos. Int. 19, 1251–1265 (2008).
42. McColl, D. J., Abel, R. L., Spears, I. M. & Macho, G. A. Automated method to measure trabecular thickness from microcomputed tomographic scans and its application. Anat. Rec. Part A Discov. Mol. Cell. Evol. Biol. 288, 982–988 (2006).
43. Reissis, D. & Abel, R. L. Development of fetal trabecular micro-architecture in the humerus and femur. J. Anat. 220, 496–503 (2012).
44. Abel, R. L., Laurini, C. R. & Richter, M. A palaeobiologist’s guide to ‘virtual’ micro-CT preparation. Palaeontol. Electron. 15, 6T (2012).
45. Karunaratne, A. et al. Significant deterioration in nanomechanical quality occurs through incomplete extracellular mineralization in rachitic bone: Evidence from in-situ synchrotron X-ray scattering and backscattered electron imaging. J. Bone Miner. Res. 27, 876–890 (2012).
46. Karunaratne, A., Terrill, N. J. & Gupta, H. S. Chapter Nineteen—Synchrotron X-Ray Nanomechanical Imaging of Mineralized Fiber Composites. In Methods in Enzymology (ed. De Yoreo, J. J.) Vol. 532, 415–473 (Academic Press, 2013).
47. Morgan, E. F. & Keaveny, T. M. Dependence of yield strain of human trabecular bone on anatomic site. J. Biomech. 34, 569–577 (2001).
48. Fratzl, P. Collagen: Structure and Mechanics, an Introduction (Springer, Boston, 2008).
49. Ascenzi, A., Bonucci, E., Generali, P., Ripamonti, A. & Roveri, N. Orientation of apatite in single osteon samples as studied by pole figures. Calcif. Tissue Int. 29, 101–105 (1979).
50. Jaschouz, D. et al. Pole figure analysis of mineral nanoparticle orientation in individual trabecula of human vertebral bone. J. Appl. Cryst. 36, 494–498 (2003).
51. Barth, H. D. et al. Characterization of the effects of x-ray irradiation on the hierarchical structure and mechanical properties of human cortical bone. Biomaterials 32, 8892–8904 (2011).

Acknowledgements
Synchrotron beamtime was funded by the Science and Technology Facilities Council (STFC). Funding was also provided by The Royal Osteoporosis Society, The Michael Uren Foundation and The Dr Mortimer & Theresa Sackler Foundation. The authors would like to thank Professor Anthony Bull for the loan of camera equipment and anonymous reviewers for insightful feedback and comment.

Author contributions
R.L.A., U.H. and J.P.C. conceived the project. R.L.A., N.T., A.K., U.H., S.M. and J.P.C. designed the study. Ethical applications, bone sample collection, analysis of records and preparation carried out by R.L.A., R.B., T.T., O.B., and S.M. Loading rig designed and built by N.T. and A.K. Synchrotron imaging experiments carried out by S.M., E.L.G., N.T., C.W., O.B., A.K., J.C., Y.W. and U.H. Image analysis and data analysis carried out by S.M., E.L.G., C.W., T.T., R.L.A. and U.H. Approving the last version of manuscript: All. S.M. takes responsibility for the integrity of the data analysis.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-69783-5.

Correspondence and requests for materials should be addressed to R.L.A.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020